Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Duality Biotherapeutics, Inc. ( (HK:9606) ) has shared an announcement.
Duality Biotherapeutics, Inc. announced that its Phase III clinical trial for DB-1303/BNT323 in HER2-positive unresectable or metastatic breast cancer patients met its primary endpoint of progression-free survival. This achievement marks a significant step towards the potential approval of DB-1303/BNT323, as the company plans to discuss a Biologics License Application with China’s National Medical Products Administration. The drug, developed in partnership with BioNTech SE, has shown promise across various cancer types and has received Fast Track and Breakthrough Therapy Designations from the FDA and NMPA, highlighting its potential impact on cancer treatment options.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$367.06 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of antibody-drug conjugates (ADCs) for cancer treatment. The company is engaged in clinical-stage research, with a particular emphasis on therapies targeting HER2-expressing advanced solid tumors.
Average Trading Volume: 267,091
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$29.84B
See more insights into 9606 stock on TipRanks’ Stock Analysis page.